Category Research

Tempus to Present Nine Abstracts at the 2024 Society for Immunotherapy of Cancer Annual Meeting

Tempus AI, Inc. (NASDAQ: TEM), a leader in utilizing AI to advance precision medicine and patient care, announced today that nine abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place…

Read MoreTempus to Present Nine Abstracts at the 2024 Society for Immunotherapy of Cancer Annual Meeting

Gilead Presents Late-Breaking Data at HIV Glasgow, Advancing Efforts to End the Epidemic

Gilead Sciences, Inc. (Nasdaq: GILD) has announced the upcoming presentation of over 40 HIV research studies at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13. The research includes late-breaking findings, with…

Read MoreGilead Presents Late-Breaking Data at HIV Glasgow, Advancing Efforts to End the Epidemic

BridgeBio Case Study on Portfolio Theory in Biomedical Innovation Published in JPM

BridgeBio Pharma, Inc. (Nasdaq: BBIO), an innovative biopharmaceutical company focused on treating genetic diseases, has announced the publication of a case study, “Applications of Portfolio Theory to Accelerating Biomedical Innovation,” in The Journal of Portfolio Management. This study, which highlights…

Read MoreBridgeBio Case Study on Portfolio Theory in Biomedical Innovation Published in JPM

Neurocrine Biosciences Reveals INGREZZA® Data: Most Achieve Tardive Dyskinesia Remission

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) showcased findings from the long-term KINECT®-4 study, revealing that nearly 60% of participants achieved remission from tardive dyskinesia after 48 weeks of treatment with once-daily INGREZZA® (valbenazine) capsules. This research, titled “Remission of Tardive Dyskinesia…

Read MoreNeurocrine Biosciences Reveals INGREZZA® Data: Most Achieve Tardive Dyskinesia Remission

Medidata and Cogstate Partner to Enhance Neurology Clinical Trials with AI Solutions

Medidata, a brand of Dassault Systèmes and a leading provider of clinical trial solutions, has partnered with Cogstate, a leader in neuroscience solutions, to transform clinical trials and outcome measurements for central nervous system (CNS) diseases, including neurodegenerative, psychiatric, motor,…

Read MoreMedidata and Cogstate Partner to Enhance Neurology Clinical Trials with AI Solutions

AbbVie Acquires Aliada Therapeutics to Strengthen Alzheimer’s and Neuroscience Commitment

AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Aliada Therapeutics, a biotechnology firm focused on developing therapies using innovative blood-brain barrier (BBB)-crossing technology aimed at treating complex central nervous system (CNS) diseases. Aliada’s lead investigational asset, ALIA-1758, is…

Read MoreAbbVie Acquires Aliada Therapeutics to Strengthen Alzheimer’s and Neuroscience Commitment

Merck and Moderna Launch Phase 3 Trial of V940 and KEYTRUDA® Combo in Non-Small Cell Lung Cancer

Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the launch of INTerpath-009, a Phase 3 randomized clinical trial investigating V940 (mRNA-4157), an individualized neoantigen therapy (INT), combined with KEYTRUDA® (pembrolizumab),…

Read MoreMerck and Moderna Launch Phase 3 Trial of V940 and KEYTRUDA® Combo in Non-Small Cell Lung Cancer